4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME
The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.
The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.
Changes can result in bacterial contamination, loss of drug activity, and inflammation
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.
Topline data results are expected in February 2025.
Learn about Glaucoma, Glaucoma signs and symptoms, and how to prevent blindness from Gluacoma
This Viewpoint discusses the ophthalmic device, red light therapy, for myopia treatment in children and adolescents in China, including its development and use, safety concerns,…
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
KOLOA, Hawaii — Patients with diabetic retinopathy need special care while pregnant, according to a speaker at Retina 2025. Irena Tsui, MD, said hormonal, metabolic…
This cohort study examines additional data for children from the Bifocal Lenses in Nearsighted Kids (BLINK) Study to determine whether axial eye growth increases after…